Health In Tech Inc. Class A Common Stock (HIT)
Fast GrowerFairStock Score: 30/100 — RISKY
Key Financials
| Current Price | $1.06 |
| Market Cap | $104M |
| P/E Ratio | -53 |
| ROE | -4.52% |
| Dividend Yield | —% |
| Sector | Technology |
Strengths
- Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
- Altman Z-Score of 11.6 confirms minimal bankruptcy risk and strong solvency
- Revenue growth of 53.1% demonstrates strong top-line momentum
Concerns
- Trades significantly above Graham Number ($0) with negative 327% margin of safety—limited downside protection
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
AI Analysis
Health In Tech Inc. Class A Common Stock is a micro-cap technology company valued at $104 million. Revenue stands at $33 million, though the company is currently unprofitable. From a quality standpoint, Health shows Altman Z-Score of 11.6 confirms fortress-level solvency and modest 8% ROE. On valuation, the stock is commanding a steep 75.5x multiple, with trades far above its Graham Number ($0) with no margin of safety. Growth dynamics show revenue growing at 53.1% and profit growth of -109.9%. Our composite FairStock Score of 30/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
Health's 53% revenue growth trajectory could accelerate as it captures additional market share in the technology sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
At 76x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer